The federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are a critical source of non-dilutive funding for early-stage companies. The National Cancer Institute (NCI), the largest National Institutes of Health (NIH) organization, offers SBIR and STTR programs that provide approximately $200 million annually to US small businesses for developing and commercializing novel cancer technologies. In addition to funding, the NCI SBIR Development Center offers various commercialization resources to support small businesses in getting their products into the market.

Join this webinar to learn about:

• An overview of federal SBIR/STTR programs at the National Institutes of Health (NIH) with specifics relating to the National Cancer Institute (NCI), the largest NIH Institute.
• Funding opportunities for startups, academic spinout companies, and early-stage academic entrepreneurs (e.g., postdoctoral fellows), such as the NCI SBIR Innovative Concept Award and the Small Business Transition Grant for New Entrepreneurs
• Tips for writing competitive SBIR/STTR grant proposals. Commercialization resources for applicants and awardees

Dr. Swamy Tripurani is a Program Director at the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute (NCI). Dr. Tripurani oversees a portfolio of grants and contracts to support the development of innovative cancer therapeutics, digital health technologies, and therapeutic devices by small businesses. He also co-manages the CARE (Connecting Awardees with Regulatory Experts) program, which fosters interactions between NCI-funded small businesses and the Food and Drug Administration (FDA). Before joining NCI, Dr. Tripurani worked as a regulatory scientist at the FDA for eight years. Dr. Tripurani earned his Ph.D. in Genetics and Developmental Biology from West Virginia University and completed his postdoctoral research training focused on gynecologic cancers and reproductive disorders at Baylor College of Medicine.